Table 1

Summary results of an independent 2015 survey of practising gastroenterologists performed by Apex Healthcare Consulting

UK (n=50)USA (n=52)
‘CD patients are at moderate-to-high risk of relapse throughout their lives’Agree—80% (40)Agree—79% (41)
‘There is a need for an assay that would predict clinical outcome and probability of relapse in CD’Agree—98% (49)Agree—94% (49)
Would you use a test to predict clinical outcome and probability of relapse even if you could not change your treatment approach?Yes—58% (29)Yes—54% (28)
Would you use a test to predict clinical outcome and probability of relapse if it enabled you to alter your treatment approach?Yes—100% (50)Yes—100% (52)
How many days following a test to predict clinical outcome and probability of relapse would you require the results for this to be useful?10 days (mean)9 days (mean)
  • Gastroenterologists: clinically active attending physicians (USA) or consultants (UK) with 5–30 years specialty experience, including IBD caseload. Survey funded by Wellcome Trust (Interim Translational Award 099450/Z/12/Z).

  • CD, Crohn’s disease; IBD, inflammatory bowel disease.